IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 10,188 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 67.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,385 shares of the biotechnology company’s stock after purchasing an additional 10,188 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.09% of Arcturus Therapeutics worth $330,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Arcturus Therapeutics by 9.1% in the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 42,636 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Arcturus Therapeutics during the 1st quarter worth approximately $299,000. Invesco Ltd. increased its position in Arcturus Therapeutics by 83.1% in the 1st quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 15,836 shares during the period. Jacobs Levy Equity Management Inc. increased its position in Arcturus Therapeutics by 20.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company’s stock valued at $1,526,000 after acquiring an additional 24,583 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Arcturus Therapeutics during the first quarter valued at $244,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARCT has been the topic of several analyst reports. Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, October 23rd. Guggenheim downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. Zacks Research cut Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Finally, Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Hold” and a consensus price target of $31.71.

Arcturus Therapeutics Trading Down 4.5%

Shares of Arcturus Therapeutics stock opened at $9.44 on Thursday. The business has a 50-day moving average price of $18.27 and a two-hundred day moving average price of $14.84. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $24.17. The company has a market cap of $256.39 million, a P/E ratio of -4.23 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The company had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.